An Open-label Pilot Study of Purified Tea-derived Epicatechin to Improve Mitochondrial Function, Strength and Skeletal Muscle Exercise Response in Becker Muscular Dystrophy.

Trial Profile

An Open-label Pilot Study of Purified Tea-derived Epicatechin to Improve Mitochondrial Function, Strength and Skeletal Muscle Exercise Response in Becker Muscular Dystrophy.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Mar 2017

At a glance

  • Drugs Epicatechin (Primary)
  • Indications Muscular dystrophies
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Mar 2017 Planned End Date changed from 1 May 2014 to 1 Jul 2018.
    • 10 Mar 2017 Planned primary completion date changed from 1 May 2014 to 1 Jan 2018.
    • 10 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top